castle trial crohn's disease
Castle Trial vs Anti‑TNF Therapy: Chronic Disease Management Wins?
The early results from the CASTLE trial, where 60% of participants reported a significant drop in bowel inflammation after two months, suggest that B-cell-targeted CAR-T therapy may outperform anti-TNF agents in managing refractory Crohn’s disease. Medical Disclaimer: This article is for informational purposes only and does not constitute medical